Fresh from the notebook.
Clear explanations. A pharma perspective. Follow wherever the science takes us.
Choosing siRNA Companies: What PCSK9 and ALK7 Reveal About Delivery and New Targets
As of October 1, 2026 (KST) Let’s look at why siRNA deals keep coming—and how to choose among the companies. Start with why PCSK9 is relatively accessible and when an early lead in a new target such as ALK7 can…
Why Novo and Lilly Keep Looking for Longer-Acting Shots: Deals, Delivery Technologies, and the PK That Matters
As of October 1, 2026 (KST) We already have once-weekly obesity drugs. So why do Novo Nordisk and Eli Lilly keep exploring technologies that last even longer? Let’s work through the practical reasons: helping patients tolerate treatment, reach a useful…